Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics

Rhea-AI Summary

Aprea Therapeutics (Nasdaq: APRE) announced two poster presentations at the EORTC‑NCI‑AACR International Conference on Molecular Targets and Cancer Therapeutics in Boston, Oct 22–26, 2025.

Two abstracts — updated phase 1 data for APR-1051 (WEE1 inhibitor) and updated phase 1/2a data for ATRN-119 (ATR inhibitor) — will be shown as posters on Oct 24, 2025, 12:30–16:00 ET in Exhibit Hall D. Posters will be posted on Aprea’s Investor Resources page the day of presentation.

DOYLESTOWN, Pa., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today announced that two abstracts on its clinical programs, APR-1051 amd ATRN-119, have been accepted for poster presentation at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics, taking place October 22 - 26, 2025 at the Hynes Convention Center in Boston, Massachusetts.

Poster Details
Title:	Early safety and efficacy of APR-1051, a novel WEE1 inhibitor, in patients with cancer-associated gene alterations: Updated data from ACESOT-1051 phase 1 trial
Lead author:	Anthony Tolcher MD, FRCPC
Presenter:	Philippe Pultar, MD
Session:	Poster Session B
Session date/ time:	Friday, October 24th, 12:30 - 16:00 ET
Location:	Exhibit Hall D, Hynes Convention Center
Title:	Updated data from ABOYA-119: A phase 1/2a trial of ATRN-119, a novel macrocyclic ATR inhibitor, in patients with advanced solid tumors harboring DNA damage
Lead author:	Amit Mahipal MD
Presenter:	Oren Gilad, PhD
Session:	Poster Session B
Session date/ time:	Friday, October 24th, 12:30 - 16:00 ET
Location:	Exhibit Hall D, Hynes Convention Center
Copies of the posters will be available on the “Investor Resources” page of the Aprea corporate website on the day of the presentations.

About Aprea
Aprea’s mission is to develop novel cancer therapies that target cancer cells directly, while sparing healthy ones. By exploiting unique vulnerabilities in cancer cell mutations, this approach is designed to eradicate tumors while minimizing harm to normal tissues, thereby reducing the risk of toxicity often associated with conventional chemotherapy and other treatments. Aprea’s clinical programs include APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a macrocyclic small molecule ATR inhibitor, both currently in development for solid tumor indications. For more information, please visit the company website at www.aprea.com.

The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.

Forward-Looking Statement
Certain information contained in this press release includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended related to our study analyses, clinical trials, regulatory submissions, and projected cash position. We may, in some cases use terms such as “future,” “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “targeting,” “confidence,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team and on information currently available to management that involve risks, potential changes in circumstances, assumptions, and uncertainties. All statements contained in this press release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, including timing considerations and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including, without limitation, risks related to the success, timing, and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of our ongoing clinical trials, our understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs, our ability to continue as a going concern, and the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to update such forward-looking statements for any reason, except as required by law.

Investor Contact:
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com      

FAQ

When will Aprea (APRE) present APR-1051 and ATRN-119 at the EORTC‑NCI‑AACR conference?

Both posters are scheduled for Oct 24, 2025, 12:30–16:00 ET in Exhibit Hall D at the Hynes Convention Center.

What data will Aprea (APRE) present for APR-1051 at the Oct 24, 2025 poster session?

An updated phase 1 poster presenting early safety and efficacy of APR-1051 in patients with cancer-associated gene alterations.

What will Aprea (APRE) present about ATRN-119 at the Oct 24, 2025 poster session?

Updated data from the ABOYA-119 phase 1/2a trial of ATRN-119 in advanced solid tumors with DNA damage will be presented.

Who are the presenters for Aprea’s posters at the Oct 24, 2025 session?

APR-1051 poster presenter: Philippe Pultar, MD; ATRN-119 poster presenter: Oren Gilad, PhD.

Where can investors access Aprea (APRE) poster copies for the Oct 24, 2025 presentations?

Copies will be available on Aprea’s Investor Resources webpage on the day of the presentations.

What are the clinical modalities of Aprea’s programs APR-1051 and ATRN-119 (APRE)?

APR-1051 is an oral small-molecule WEE1 inhibitor; ATRN-119 is a macrocyclic small-molecule ATR inhibitor, both in clinical development for solid tumors.